# Study of Safety and Efficacy of RVL-1201 in the Treatment of Blepharoptosis

> **NCT03565887** · PHASE3 · COMPLETED · sponsor: **RVL Pharmaceuticals, Inc.** · enrollment: 164 (actual)

## Conditions studied

- Blepharoptosis

## Interventions

- **DRUG:** RVL-1201
- **OTHER:** Vehicle ophthalmic solution

## Key facts

- **NCT ID:** NCT03565887
- **Lead sponsor:** RVL Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-28
- **Primary completion:** 2019-04-11
- **Final completion:** 2019-04-22
- **Target enrollment:** 164 (ACTUAL)
- **Last updated:** 2020-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03565887

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03565887, "Study of Safety and Efficacy of RVL-1201 in the Treatment of Blepharoptosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03565887. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*